APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

CGRP Targeting Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CGRP Targeting Drugs Market Analysis and Forecast 2026-2032

Report ID 173976700227 December 2025195 pages

Choose your research edition.

Industry ResearchCGRP Targeting Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CGRP Targeting Drugs Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal CGRP Targeting Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CGRP Targeting Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CGRP Targeting Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global CGRP Targeting Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CGRP Targeting Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CGRP Targeting Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CGRP Targeting Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CGRP Targeting Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CGRP Targeting Drugs include Alder Therapeutics, AbbVie Inc., Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CGRP Targeting Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CGRP Targeting Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for CGRP Targeting Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CGRP Targeting Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CGRP Targeting Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CGRP Targeting Drugs revenue, projected growth trends, production technology, application and end-user industry.

CGRP Targeting Drugs Segment by Company

Alder Therapeutics

AbbVie Inc.

Amgen Inc.

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Lilly Inc.

Lundbeck

Novartis International AG

Teva

CGRP Targeting Drugs Segment by Type

CGRP Receptor Antagonists

CGRP Monoclonal Antibodies

CGRP Targeting Drugs Segment by Application

Specialty Clinic

Hospital

Others

CGRP Targeting Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Targeting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CGRP Targeting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Targeting Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CGRP Targeting Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CGRP Targeting Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CGRP Targeting Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CGRP Targeting Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CGRP Receptor Antagonists Major Player Table 3. CGRP Monoclonal Antibodies Major Player Table 4. Global CGRP Targeting Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Specialty Clinic Major Player Table 6. Hospital Major Player Table 7. Others Major Player Table 8. CGRP Targeting Drugs Industry Trends Table 9. CGRP Targeting Drugs Industry Drivers Table 10. CGRP Targeting Drugs Industry Opportunities and Challenges Table 11. CGRP Targeting Drugs Industry Restraints Table 12. Global CGRP Targeting Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global CGRP Targeting Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global CGRP Targeting Drugs Market Share by Region (2021-2026) Table 15. Global CGRP Targeting Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global CGRP Targeting Drugs Market Share by Region (2027-2032) Table 17. Global CGRP Targeting Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global CGRP Targeting Drugs Revenue Market Share by Players (2021-2026) Table 19. Global CGRP Targeting Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global CGRP Targeting Drugs Key Players Headquarters & Area Served Table 21. Global CGRP Targeting Drugs Players, Product Type & Application Table 22. Global CGRP Targeting Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global CGRP Targeting Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global CGRP Targeting Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global CGRP Targeting Drugs Revenue Market Share by Type (2021-2026) Table 29. Global CGRP Targeting Drugs Revenue Market Share by Type (2027-2032) Table 30. Global CGRP Targeting Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global CGRP Targeting Drugs Revenue Market Share by Application (2021-2026) Table 34. Global CGRP Targeting Drugs Revenue Market Share by Application (2027-2032) Table 35. Alder Therapeutics Company Information Table 36. Alder Therapeutics Business Overview Table 37. Alder Therapeutics CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Alder Therapeutics CGRP Targeting Drugs Product Portfolio Table 39. Alder Therapeutics Recent Development Table 40. AbbVie Inc. Company Information Table 41. AbbVie Inc. Business Overview Table 42. AbbVie Inc. CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. AbbVie Inc. CGRP Targeting Drugs Product Portfolio Table 44. AbbVie Inc. Recent Development Table 45. Amgen Inc. Company Information Table 46. Amgen Inc. Business Overview Table 47. Amgen Inc. CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Amgen Inc. CGRP Targeting Drugs Product Portfolio Table 49. Amgen Inc. Recent Development Table 50. Daiichi Sankyo Co., Ltd. Company Information Table 51. Daiichi Sankyo Co., Ltd. Business Overview Table 52. Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio Table 54. Daiichi Sankyo Co., Ltd. Recent Development Table 55. Pfizer Inc. Company Information Table 56. Pfizer Inc. Business Overview Table 57. Pfizer Inc. CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Inc. CGRP Targeting Drugs Product Portfolio Table 59. Pfizer Inc. Recent Development Table 60. Lilly Inc. Company Information Table 61. Lilly Inc. Business Overview Table 62. Lilly Inc. CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Lilly Inc. CGRP Targeting Drugs Product Portfolio Table 64. Lilly Inc. Recent Development Table 65. Lundbeck Company Information Table 66. Lundbeck Business Overview Table 67. Lundbeck CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Lundbeck CGRP Targeting Drugs Product Portfolio Table 69. Lundbeck Recent Development Table 70. Novartis International AG Company Information Table 71. Novartis International AG Business Overview Table 72. Novartis International AG CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Novartis International AG CGRP Targeting Drugs Product Portfolio Table 74. Novartis International AG Recent Development Table 75. Teva Company Information Table 76. Teva Business Overview Table 77. Teva CGRP Targeting Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Teva CGRP Targeting Drugs Product Portfolio Table 79. Teva Recent Development Table 80. North America CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 81. North America CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 82. North America CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 83. North America CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 84. North America CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America CGRP Targeting Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. North America CGRP Targeting Drugs Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe CGRP Targeting Drugs Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe CGRP Targeting Drugs Revenue by Country (US$ Million) & (2027-2032) Table 94. China CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 95. China CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 96. China CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 97. China CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia CGRP Targeting Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia CGRP Targeting Drugs Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia CGRP Targeting Drugs Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA CGRP Targeting Drugs Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA CGRP Targeting Drugs Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA CGRP Targeting Drugs Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA CGRP Targeting Drugs Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA CGRP Targeting Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA CGRP Targeting Drugs Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. CGRP Targeting Drugs Image Figure 2. Global CGRP Targeting Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CGRP Targeting Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. CGRP Receptor Antagonists Image Figure 5. CGRP Monoclonal Antibodies Image Figure 6. Global CGRP Targeting Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CGRP Targeting Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Specialty Clinic Image Figure 9. Hospital Image Figure 10. Others Image Figure 11. Global CGRP Targeting Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global CGRP Targeting Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global CGRP Targeting Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global CGRP Targeting Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global CGRP Targeting Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global CGRP Targeting Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global CGRP Targeting Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global CGRP Targeting Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CGRP Targeting Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global CGRP Targeting Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America CGRP Targeting Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America CGRP Targeting Drugs Revenue Share by Type (2021-2032) Figure 24. North America CGRP Targeting Drugs Revenue Share by Application (2021-2032) Figure 25. North America CGRP Targeting Drugs Revenue Share by Country (2021-2032) Figure 26. United States CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe CGRP Targeting Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe CGRP Targeting Drugs Revenue Share by Type (2021-2032) Figure 31. Europe CGRP Targeting Drugs Revenue Share by Application (2021-2032) Figure 32. Europe CGRP Targeting Drugs Revenue Share by Country (2021-2032) Figure 33. Germany CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China CGRP Targeting Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China CGRP Targeting Drugs Revenue Share by Type (2021-2032) Figure 43. China CGRP Targeting Drugs Revenue Share by Application (2021-2032) Figure 44. Asia CGRP Targeting Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia CGRP Targeting Drugs Revenue Share by Type (2021-2032) Figure 46. Asia CGRP Targeting Drugs Revenue Share by Application (2021-2032) Figure 47. Asia CGRP Targeting Drugs Revenue Share by Region (2021-2032) Figure 48. Japan CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA CGRP Targeting Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA CGRP Targeting Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA CGRP Targeting Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA CGRP Targeting Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt CGRP Targeting Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • CGRP Receptor Antagonists
  • CGRP Monoclonal Antibodies
Applications
  • Specialty Clinic
  • Hospital
  • Others
Companies covered
  • Alder Therapeutics
  • AbbVie Inc.
  • Amgen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Pfizer Inc.
  • Lilly Inc.
  • Lundbeck
  • Novartis International AG
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CGRP Targeting Drugs Market by Type
  3. 1.2.1 Global CGRP Targeting Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CGRP Receptor Antagonists
  5. 1.2.3 CGRP Monoclonal Antibodies
  6. 1.3 CGRP Targeting Drugs Market by Application
  7. 1.3.1 Global CGRP Targeting Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Specialty Clinic
  9. 1.3.3 Hospital
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 CGRP Targeting Drugs Market Dynamics
  1. 2.1 CGRP Targeting Drugs Industry Trends
  2. 2.2 CGRP Targeting Drugs Industry Drivers
  3. 2.3 CGRP Targeting Drugs Industry Opportunities and Challenges
  4. 2.4 CGRP Targeting Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CGRP Targeting Drugs Market Perspective (2021-2032)
  2. 3.2 Global CGRP Targeting Drugs Growth Trends by Region
  3. 3.2.1 Global CGRP Targeting Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CGRP Targeting Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global CGRP Targeting Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CGRP Targeting Drugs Revenue by Players
  2. 4.1.1 Global CGRP Targeting Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global CGRP Targeting Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CGRP Targeting Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CGRP Targeting Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CGRP Targeting Drugs Key Players Headquarters & Area Served
  7. 4.4 Global CGRP Targeting Drugs Players, Product Type & Application
  8. 4.5 Global CGRP Targeting Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CGRP Targeting Drugs Market CR5 and HHI
  11. 4.6.3 2025 CGRP Targeting Drugs Tier 1, Tier 2, and Tier 3
5 CGRP Targeting Drugs Market Size by Type
  1. 5.1 Global CGRP Targeting Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 5.3 Global CGRP Targeting Drugs Revenue Market Share by Type (2021-2032)
6 CGRP Targeting Drugs Market Size by Application
  1. 6.1 Global CGRP Targeting Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CGRP Targeting Drugs Revenue by Application (2021-2032)
  3. 6.3 Global CGRP Targeting Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alder Therapeutics
  2. 7.1.1 Alder Therapeutics Company Information
  3. 7.1.2 Alder Therapeutics Business Overview
  4. 7.1.3 Alder Therapeutics CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alder Therapeutics CGRP Targeting Drugs Product Portfolio
  6. 7.1.5 Alder Therapeutics Recent Developments
  7. 7.2 AbbVie Inc.
  8. 7.2.1 AbbVie Inc. Company Information
  9. 7.2.2 AbbVie Inc. Business Overview
  10. 7.2.3 AbbVie Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Inc. CGRP Targeting Drugs Product Portfolio
  12. 7.2.5 AbbVie Inc. Recent Developments
  13. 7.3 Amgen Inc.
  14. 7.3.1 Amgen Inc. Company Information
  15. 7.3.2 Amgen Inc. Business Overview
  16. 7.3.3 Amgen Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Inc. CGRP Targeting Drugs Product Portfolio
  18. 7.3.5 Amgen Inc. Recent Developments
  19. 7.4 Daiichi Sankyo Co., Ltd.
  20. 7.4.1 Daiichi Sankyo Co., Ltd. Company Information
  21. 7.4.2 Daiichi Sankyo Co., Ltd. Business Overview
  22. 7.4.3 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio
  24. 7.4.5 Daiichi Sankyo Co., Ltd. Recent Developments
  25. 7.5 Pfizer Inc.
  26. 7.5.1 Pfizer Inc. Company Information
  27. 7.5.2 Pfizer Inc. Business Overview
  28. 7.5.3 Pfizer Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Inc. CGRP Targeting Drugs Product Portfolio
  30. 7.5.5 Pfizer Inc. Recent Developments
  31. 7.6 Lilly Inc.
  32. 7.6.1 Lilly Inc. Company Information
  33. 7.6.2 Lilly Inc. Business Overview
  34. 7.6.3 Lilly Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lilly Inc. CGRP Targeting Drugs Product Portfolio
  36. 7.6.5 Lilly Inc. Recent Developments
  37. 7.7 Lundbeck
  38. 7.7.1 Lundbeck Company Information
  39. 7.7.2 Lundbeck Business Overview
  40. 7.7.3 Lundbeck CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lundbeck CGRP Targeting Drugs Product Portfolio
  42. 7.7.5 Lundbeck Recent Developments
  43. 7.8 Novartis International AG
  44. 7.8.1 Novartis International AG Company Information
  45. 7.8.2 Novartis International AG Business Overview
  46. 7.8.3 Novartis International AG CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis International AG CGRP Targeting Drugs Product Portfolio
  48. 7.8.5 Novartis International AG Recent Developments
  49. 7.9 Teva
  50. 7.9.1 Teva Company Information
  51. 7.9.2 Teva Business Overview
  52. 7.9.3 Teva CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Teva CGRP Targeting Drugs Product Portfolio
  54. 7.9.5 Teva Recent Developments
8 North America
  1. 8.1 North America CGRP Targeting Drugs Revenue (2021-2032)
  2. 8.2 North America CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America CGRP Targeting Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America CGRP Targeting Drugs Revenue by Type (2027-2032)
  5. 8.3 North America CGRP Targeting Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America CGRP Targeting Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America CGRP Targeting Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America CGRP Targeting Drugs Revenue by Application (2027-2032)
  9. 8.5 North America CGRP Targeting Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America CGRP Targeting Drugs Revenue by Country
  11. 8.6.1 North America CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CGRP Targeting Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America CGRP Targeting Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CGRP Targeting Drugs Revenue (2021-2032)
  2. 9.2 Europe CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe CGRP Targeting Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe CGRP Targeting Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe CGRP Targeting Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe CGRP Targeting Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe CGRP Targeting Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe CGRP Targeting Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe CGRP Targeting Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe CGRP Targeting Drugs Revenue by Country
  11. 9.6.1 Europe CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CGRP Targeting Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe CGRP Targeting Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CGRP Targeting Drugs Revenue (2021-2032)
  2. 10.2 China CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China CGRP Targeting Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China CGRP Targeting Drugs Revenue by Type (2027-2032)
  5. 10.3 China CGRP Targeting Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China CGRP Targeting Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China CGRP Targeting Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China CGRP Targeting Drugs Revenue by Application (2027-2032)
  9. 10.5 China CGRP Targeting Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CGRP Targeting Drugs Revenue (2021-2032)
  2. 11.2 Asia CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia CGRP Targeting Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia CGRP Targeting Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia CGRP Targeting Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia CGRP Targeting Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia CGRP Targeting Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia CGRP Targeting Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia CGRP Targeting Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia CGRP Targeting Drugs Revenue by Country
  11. 11.6.1 Asia CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CGRP Targeting Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia CGRP Targeting Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CGRP Targeting Drugs Revenue (2021-2032)
  2. 12.2 SAMEA CGRP Targeting Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CGRP Targeting Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CGRP Targeting Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA CGRP Targeting Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CGRP Targeting Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CGRP Targeting Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CGRP Targeting Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA CGRP Targeting Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CGRP Targeting Drugs Revenue by Country
  11. 12.6.1 SAMEA CGRP Targeting Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CGRP Targeting Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CGRP Targeting Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst